Assessing the Risk of Secondary Malignant Neoplasms Among Patients with Diffuse Large B-cell Lymphoma

A study assessed the risk of secondary malignant neoplasms (SMNs) among patients with a diffuse large B-cell lymphoma (DLBCL) diagnosis involving different primary extranodal sites. The results appeared in the journal Translational Oncology.

Researchers analyzed 40,714 patients diagnosed with stage I/II DLBCL, with data gleaned from the Surveillance, Epidemiology, and End Results database from 1983 to 2015.They used standardized incidence ratio (SIR) and absolute excess risk (AER) to assess the risk of SMNs.

According to the results, the risk of SMN was significantly higher in extranodal DLBCL than in the U.S. general population (SIR, 1.18; 95% confidence interval, 1.11-1.26). The study also identified multiple site-specific risk patterns, including a 22%, 44%, 66%, 123%, and 151% increased risk of SMN 10 years after primary gastrointestinal tract, head/neck, skeletal, lung, and liver/pancreas DLBCL diagnosis, respectively.

Moreover, the researchers noted, there was a significant decreased risk of SMN with increasing age at diagnosis for primary gastrointestinal tract and skeletal DLBCL.

The strategies for cancer surveillance after extranodal DLBCL diagnosis may need to be individualized according to the subsite of extranodal DLBCL,” the researchers concluded.